Phase
Condition
Kidney Cancer
Carcinoma
Cancer/tumors
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Pre-Surgery Inclusion Criteria:
Primary-intact resectable renal cell cancer, without known distant metastasis and bescheduled to have surgery with curative intent;
Tumor size greater than or equal to 5 cm OR macroscopic nodes OR renal vein thrombusOR vena cava thrombus by radiologic evaluation
Performance status (Zubrod / ECOG-WHO scale)less than or equal to 1 and lifeexpectancy of greater than three months, within 2 weeks of surgery.
Women of child-bearing potential must have a negative urine or serum pregnancy testwithin 2 weeks of surgery.
Signed written informed consent.
Exclusion
Pre-Surgery Exclusion Criteria:
Prior chemo-, hormonal, immuno- or radiotherapy for renal cell cancer;
History of primary or secondary immunodeficiency, or patients using immunosuppressivedrugs, e.g. systemic corticosteroids, cyclosporin A;
Current malignancies at other sites or previous other cancer within the last 5 years,with the exception of adequately treated cone-biopsied in situ carcinoma of the cervixuteri or basal or squamous cell carcinoma of the skin;
Embolization of the renal artery prior to nephrectomy;
Known distant metastases;
Active, uncontrolled infection or other serious medical illnesses. Eligibility Assessment:
(between 2 weeks pre- and 4 weeks post-surgery) Prior to randomization and entry into the tumor evaluation phase, all subjects must undergotesting to confirm that they are free of distant metastatic disease, and that they meet allother criteria. Eligibility Criteria which must be assessed and confirmed prior to randomization:
No evidence of metastatic or residual renal carcinoma as documented by all of thefollowing: abdominal/pelvis CT scan; chest CT scan; and brain CT or MRI scan.
Provide Antigenics with greater than or equal to 7 grams of viable tumor tissue
Adequate bone marrow function.
Adequate renal and hepatic function.
Adequate cardiac function.
Signed written informed consent.
Patients must be willing to be followed during the course of tumor evaluation andfollow-up phases.
Male or female patients of child producing potential must agree to use adequatecontraception during the treatment/observation phase of the study.
Patients must not use any other investigational drug for four weeks prior to the startof the tumor evaluation phase and throughout the tumor evaluation phase of the study.
Study Design
Study Description
Connect with a study center
Vienna,
AustriaSite Not Available
Kortrijk,
BelgiumSite Not Available
Liege,
BelgiumSite Not Available
Calgary, Alberta
CanadaSite Not Available
Vancouver, British Columbia
CanadaSite Not Available
Victoria, British Columbia
CanadaSite Not Available
London, Ontario
CanadaSite Not Available
Toronto, Ontario
CanadaSite Not Available
Montreal, Quebec
CanadaSite Not Available
Quebec,
CanadaSite Not Available
Lille,
FranceSite Not Available
Strasbourg,
FranceSite Not Available
Toulouse Cedex,
FranceSite Not Available
Villejuif Cedex,
FranceSite Not Available
Beer-Yaacob, Zerifin
IsraelSite Not Available
Haifa,
IsraelSite Not Available
Holon,
IsraelSite Not Available
Jerusalem,
IsraelSite Not Available
Tel-Hashomer,
IsraelSite Not Available
Oslo,
NorwaySite Not Available
Stavanger,
NorwaySite Not Available
Bialystok,
PolandSite Not Available
Gdansk,
PolandSite Not Available
Kielce,
PolandSite Not Available
Krakow,
PolandSite Not Available
Lublin,
PolandSite Not Available
Szczecin,
PolandSite Not Available
Warsaw,
PolandSite Not Available
Barcelona,
SpainSite Not Available
Madrid,
SpainSite Not Available
Valencia,
SpainSite Not Available
Gothenburg,
SwedenSite Not Available
Lund,
SwedenSite Not Available
Umea,
SwedenSite Not Available
Uppsala,
SwedenSite Not Available
Bristol,
United KingdomSite Not Available
London,
United KingdomSite Not Available
Anchorage, Alaska
United StatesSite Not Available
Tucson, Arizona
United StatesSite Not Available
Los Angeles, California
United StatesSite Not Available
San Francisco, California
United StatesSite Not Available
Denver, Colorado
United StatesSite Not Available
Farmington, Connecticut
United StatesSite Not Available
Boca Raton, Florida
United StatesSite Not Available
Miami, Florida
United StatesSite Not Available
Tampa, Florida
United StatesSite Not Available
Atlanta, Georgia
United StatesSite Not Available
Chicago, Illinois
United StatesSite Not Available
Maywood, Illinois
United StatesSite Not Available
Iowa City, Iowa
United StatesSite Not Available
Kansas City, Kansas
United StatesSite Not Available
Gretna, Louisiana 70056
United StatesSite Not Available
Baltimore, Maryland 21287
United StatesSite Not Available
Boston, Massachusetts
United StatesSite Not Available
Rochester, Minnesota 55905
United StatesSite Not Available
St. Louis, Missouri
United StatesSite Not Available
Albuquerque, New Mexico
United StatesSite Not Available
Manhasset, New York
United StatesSite Not Available
New York City, New York
United StatesSite Not Available
Charlotte, North Carolina
United StatesSite Not Available
Winston-Salem, North Carolina
United StatesSite Not Available
Cincinatti, Ohio
United StatesSite Not Available
Cleveland, Ohio
United StatesSite Not Available
Columbus, Ohio
United StatesSite Not Available
Eugene, Oregon
United StatesSite Not Available
Portland, Oregon
United StatesSite Not Available
Philadelphia, Pennsylvania
United StatesSite Not Available
Knoxville, Tennessee
United StatesSite Not Available
Nashville, Tennessee
United StatesSite Not Available
Ft. Worth, Texas
United StatesSite Not Available
Houston, Texas
United StatesSite Not Available
South Burlington, Vermont
United StatesSite Not Available
Richmond, Virginia
United StatesSite Not Available
Seattle, Washington
United StatesSite Not Available
Milwaukee, Wisconsin
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.